secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2022-02-17T23:59:59+00:00
Accession:  0001140361-22-005849
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Insmed Q4 revenue $56.1M (+36% YoY), net loss $113M; guides 30%+ ARIKAYCE growth in 2022
--------------------------------------------------------------------------------

- Full-year 2021 revenue $188.5M (vs $164.4M); ARIKAYCE sales $159.5M US, $16.0M Japan, $12.9M Europe/ROW.
- Net loss for 2021 $434.7M ($3.88/share) vs $294.1M ($3.01/share); Q4 net loss $113.0M ($0.95/share).
- Cash and marketable securities $766.8M; company expects cash runway into 2024.
- Brensocatib Phase 3 ASPEN (bronchiectasis) 50% enrolled; topline data expected early 2023.
- Director Steinar J. Engelsen not standing for re-election at 2022 Annual Meeting; no disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036122005849/0001140361-22-005849-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036122005849/brhc10033810_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-005849

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer